Moderna Stock Today
| MRNA Stock | USD 60.20 0.87 1.42% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Moderna is trading at 60.20 as of the 6th of October 2024, a 1.42 percent decrease since the beginning of the trading day. The stock's open price was 61.07. Moderna has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Note, on April 5, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Moderna's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of December 2018 | Category Healthcare | Classification Health Care |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. The company has 384.4 M outstanding shares of which 27.61 M shares are now shorted by private and institutional investors with about 5.67 trading days to cover. More on Moderna
Moving together with Moderna Stock
Moving against Moderna Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Moderna Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, SP 500 Index, NASDAQ Health Care, Nasdaq 100, ARCA Biotechnology, NASDAQ 100 Pre, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsModerna can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moderna's financial leverage. It provides some insight into what part of Moderna's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Moderna (MRNA) is traded on NASDAQ Exchange in USA. It is located in 200 Technology Square, Cambridge, MA, United States, 02139 and employs 5,600 people. Moderna is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 23.14 B. Moderna conducts business under Biotechnology sector and is part of Health Care industry. The entity has 384.4 M outstanding shares of which 27.61 M shares are now shorted by private and institutional investors with about 5.67 trading days to cover.
Moderna currently holds about 8.35 B in cash with (3.12 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 21.73.
Check Moderna Probability Of Bankruptcy
Ownership AllocationModerna maintains a total of 384.4 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. Please note that on April 5, 2024, Representative Ro Khanna of US Congress acquired under $15k worth of Moderna's common stock.
Check Moderna Ownership Details
Moderna Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Asset Mgmt Americas Inc | 2024-06-30 | 3.9 M | |
| Capital World Investors | 2024-06-30 | 3.7 M | |
| Norges Bank | 2024-06-30 | 3.4 M | |
| Banque Pictet & Cie Sa | 2024-06-30 | 3.2 M | |
| Manufacturers Life Insurance Co | 2024-06-30 | 2.9 M | |
| Northern Trust Corp | 2024-06-30 | 2.8 M | |
| Legal & General Group Plc | 2024-06-30 | 2.6 M | |
| Amvescap Plc. | 2024-06-30 | 2.5 M | |
| Bank Of New York Mellon Corp | 2024-06-30 | 2.3 M | |
| Baillie Gifford & Co Limited. | 2024-06-30 | 43.4 M | |
| Vanguard Group Inc | 2024-06-30 | 39.6 M |
Moderna Historical Income Statement
Moderna Stock Against Markets
Moderna Corporate Management
| Shannon Klinger | Chief Secretary | Profile | |
| Brad Miller | Chief Officer | Profile | |
| Melanie MBA | Chief Officer | Profile | |
| James Mock | Chief Officer | Profile | |
| Stephane Bancel | CEO Director | Profile | |
| John Reynders | Chief Officer | Profile | |
| Dave Johnson | Chief Officer | Profile |
Additional Information and Resources on Investing in Moderna Stock
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (15.35) | Revenue Per Share 13.22 | Quarterly Revenue Growth (0.30) | Return On Assets (0.15) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.